Chemours (CC) Hisse Özeti
The Chemours Company Kuzey Amerika, Asya Pasifik, Avrupa, Orta Doğu, Afrika ve Latin Amerika'da performans kimyasalları sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 6/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 0/6 |
| Temettüler | 3/6 |
Ödüller
Risk Analizi
CC Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Chemours Company Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$15.75 |
| 52 Haftanın En Yüksek Seviyesi | US$28.67 |
| 52 Haftanın En Düşük Seviyesi | US$10.44 |
| Beta | 1.43 |
| 1 Aylık Değişim | -11.57% |
| 3 Aylık Değişim | -37.65% |
| 1 Yıllık Değişim | 29.20% |
| 3 Yıllık Değişim | -54.08% |
| 5 Yıllık Değişim | -54.33% |
| Halka arzdan bu yana değişim | -21.37% |
Son Haberler & Güncellemeler
Seeking Alpha • Aug 06
Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)
Summary Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis. At or below $15/share, CC offers 35-37% annual upside; at $20/share, the risk/reward remains attractive though more speculative. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 05
CC: PFAS Settlement Will Support Cleaner Operations And Stronger Future Outlook
Analysts have trimmed their Chemours price target from $21.00 to $19.00 as updated assumptions point to different expectations for fair value, profitability, growth and future P/E levels. What’s in the News for Chemours Chemours announced a settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims related to PFAS discharges and other alleged non compliance at its Washington Works, Fayetteville Works, and Chambers Works facilities.Recent updates
Seeking Alpha • Aug 06
Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)
Summary Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis. At or below $15/share, CC offers 35-37% annual upside; at $20/share, the risk/reward remains attractive though more speculative. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 05
CC: PFAS Settlement Will Support Cleaner Operations And Stronger Future Outlook
Analysts have trimmed their Chemours price target from $21.00 to $19.00 as updated assumptions point to different expectations for fair value, profitability, growth and future P/E levels. What’s in the News for Chemours Chemours announced a settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims related to PFAS discharges and other alleged non compliance at its Washington Works, Fayetteville Works, and Chambers Works facilities.
Anlatı Güncellemesi • Jul 22
CC: Regulatory Settlement And Margin Recovery Will Drive Re Rating Potential
Analysts have lowered their price target on Chemours to $24.67 from $26.33, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth expectations, a small change in projected profit margins, and a revised future P/E multiple. What’s in the News for Chemours BMO Capital reiterated a Buy rating on Chemours with a US$26 price target, which is close to the current median Wall Street target of US$25, according to recent analyst reports.Anlatı Güncellemesi • Jul 06
CC: PFAS Settlement And Updated Outlook Will Shape Balanced Future Expectations
Analysts have raised their Chemours fair value estimate from $17.00 to $21.00, citing updated views on discount rate assumptions, revenue growth, profit margins and potential future P/E levels. What’s in the News for Chemours Chemours agreed to a multi-site PFAS settlement with the U.S. Environmental Protection Agency, the Department of Justice, the West Virginia Department of Environmental Protection, and multiple states, with total costs reported at more than US$450 million for penalties, mitigation projects, pollution controls, and community water initiatives.
Anlatı Güncellemesi • Jun 22
CC: Raised Margins And 2026 Outlook Will Support Further Earnings Upside
Analysts maintained their $30.00 price target on Chemours, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together support keeping the prior valuation level. What’s in the News for Chemours Chemours issued earnings guidance for the second quarter of 2026, indicating an expected sequential change in consolidated net sales in a range of 15% to 20%, which the company links to seasonal trends.Anlatı Güncellemesi • Jun 04
CC: Regulatory Reset And Margin Rebound Will Drive Re Rating Potential
Analysts now cite improved assumptions for Chemours' fair value, discount rate, revenue growth, profit margin, and future P/E in raising their price target by about $10 per share. What's in the News Chemours shares fell on May 21, 2026 after the EPA eased refrigerant regulations put in place during the Biden administration, according to recent news reports.Anlatı Güncellemesi • May 15
CC: Cooling Alliance And 2026 Guidance Will Support Further Earnings Upside
Analysts have raised their price target for Chemours by $1 to $30, reflecting updated assumptions that include a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E estimate. What's in the News Chemours issued earnings guidance for the second quarter of 2026, expecting consolidated net sales to be 15% to 20% higher sequentially, citing favorable seasonal trends (Corporate Guidance).Analiz Makalesi • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...Anlatı Güncellemesi • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).Anlatı Güncellemesi • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).Anlatı Güncellemesi • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).Anlatı Güncellemesi • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.Anlatı Güncellemesi • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.Anlatı Güncellemesi • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.Analiz Makalesi • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...Anlatı Güncellemesi • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).Anlatı Güncellemesi • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.Anlatı Güncellemesi • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Anlatı Güncellemesi • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Anlatı Güncellemesi • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.Anlatı Güncellemesi • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).Anlatı Güncellemesi • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).Anlatı Güncellemesi • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.Analiz Makalesi • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...Analiz Makalesi • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...Analiz Makalesi • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...Analiz Makalesi • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...Analiz Makalesi • Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...Hissedar Getirileri
| CC | US Chemicals | US Pazar | |
|---|---|---|---|
| 7D | -5.2% | 3.5% | 4.2% |
| 1Y | 29.2% | 9.6% | 20.6% |
Getiri vs. Endüstri: CC geçen yıl % 9.6 oranında getiri sağlayan US Chemicals sektörünü aştı.
Getiri vs Piyasa: CC geçen yıl % 20.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| CC volatility | |
|---|---|
| CC Average Weekly Movement | 9.5% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: CC son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CC 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2014 | 5,700 | Denise M. Dignam | www.chemours.com |
The Chemours Company, Kuzey Amerika, Asya Pasifik, Avrupa, Orta Doğu, Afrika ve Latin Amerika'da performans kimyasalları sağlamaktadır. Şirket üç segmentte faaliyet göstermektedir: Termal ve Özel Çözümler, Titanyum Teknolojileri ve Gelişmiş Performans Malzemeleri. Termal ve Özel Çözümler segmenti, Freon ve Opteon markaları altında soğutucu akışkanlar, termal yönetim çözümleri, itici gazlar, köpük üfleme maddeleri ve özel solventler sağlamaktadır.
The Chemours Company Temel Bilgiler Özeti
| CC temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.37b |
| Kazançlar(TTM) | -US$304.00m |
| Gelir(TTM) | US$5.80b |
0.4x
P/S Oranı-7.8x
F/K OranıCC aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CC gelir tablosu (TTM) | |
|---|---|
| Gelir | US$5.80b |
| Gelir Maliyeti | US$4.90b |
| Brüt Kâr | US$893.00m |
| Diğer Giderler | US$1.20b |
| Kazançlar | -US$304.00m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.02 |
| Brüt Marj | 15.40% |
| Net Kâr Marjı | -5.24% |
| Borç/Özkaynak Oranı | -7,985.4% |
CC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.2%
Mevcut Temettü Verimi-17%
Ödeme OranıCC güvenilir bir temettü ödüyor mu?
CC temettü geçmişine ve kıyaslamalara bakın| Chemours temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Aug 14 2026 |
| Temettü Ödeme Tarihi | Sep 15 2026 |
| Eski temettüye kadar geçen günler | 4 days |
| Temettü ödeme tarihine kadar geçen günler | 36 days |
CC güvenilir bir temettü ödüyor mu?
CC temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/09 20:00 |
| Gün Sonu Hisse Fiyatı | 2026/08/07 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
The Chemours Company 18 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |